(Total Views: 256)
Posted On: 04/22/2020 5:04:53 PM
Post# of 36568
This part of the Brown article puts things in perspective.
Fundamentals of Funding
Despite the preliminary successes the companies have seen thus far, funding remains a critical part of the picture. Funding often pushes back the timeline, or worse, cancels hopes of a trial continuing. EpiVax’s and Generex’s earlier research on vaccine candidates for the H1N1 and SARS pandemics were halted largely due to funding limitations.
Still, the companies believe that this time around, it will not be as much of a barrier. “If our trials are successful, I’m sure that there will be opportunities to take a vaccine candidate even further,” Porter said. “There is government and other funding available, but there are many people trying to get it. We have many collaborations in place to move a COVID vaccine forward, … so chances for success are very good.”
https://www.browndailyherald.com/2020/04/19/p...9-vaccine/
Fundamentals of Funding
Despite the preliminary successes the companies have seen thus far, funding remains a critical part of the picture. Funding often pushes back the timeline, or worse, cancels hopes of a trial continuing. EpiVax’s and Generex’s earlier research on vaccine candidates for the H1N1 and SARS pandemics were halted largely due to funding limitations.
Still, the companies believe that this time around, it will not be as much of a barrier. “If our trials are successful, I’m sure that there will be opportunities to take a vaccine candidate even further,” Porter said. “There is government and other funding available, but there are many people trying to get it. We have many collaborations in place to move a COVID vaccine forward, … so chances for success are very good.”
https://www.browndailyherald.com/2020/04/19/p...9-vaccine/
(1)
(0)
